滑膜肉瘤乏氧微环境介导HIF-1α/miR-130a/FRZB-ASPN/CCL2通路招募巨噬细胞的机理研究

批准号:
81902730
项目类别:
青年科学基金项目
资助金额:
21.0 万元
负责人:
李建龙
依托单位:
学科分类:
H1818.肿瘤免疫治疗
结题年份:
2022
批准年份:
2019
项目状态:
已结题
项目参与者:
--
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
滑膜肉瘤存在乏氧微环境并招募大量肿瘤相关巨噬细胞,而具体机制尚未明确。课题组前期研究发现乏氧条件或导入HIF-1α质粒可上调滑膜肉瘤miR-130a表达并招募巨噬细胞;抑制miR-130a可上调FRZB表达;FRZB可能与ASPN存在互作关系;乏氧条件下抑制miR-130a可逆转下调趋化因子CCL2并减少巨噬细胞招募。本研究将通过转录调控、转录后抑制、蛋白互作等层面进一步全面探索HIF-1α靶向启动子区上调miR-130a表达;miR-130a直接靶击FRZB减少其表达、降低与ASPN蛋白互作而增加ASPN水平,进一步激活AKT信号通路促进CCL2分泌招募巨噬细胞导致滑膜肉瘤恶化的机制。揭示滑膜肉瘤乏氧微环境中HIF-1α/miR-130a/FRZB-ASPN/CCL2通路对肿瘤相关巨噬细胞的招募调控,以及关键节点对滑膜肉瘤的诊断及预后判断意义,为滑膜肉瘤微环境靶向治疗提供新的实验依据。
英文摘要
Synovial sarcoma tissue has a hypoxic microenvironment and recruits a large number of tumor-associated macrophages (TAMs). However, the specific mechanism has not been well clarified. Previous studies in our research group found that hypoxia or introduction of HIF-1α plasmid could up-regulate miR-130a and recruited macrophages; inhibition of miR-130a up-regulated FRZB expression; FRZB may interact with ASPN; inhibition of miR-130a under hypoxic conditions decreased CCL2 and reduced the recruitment of macrophage. This study will further explore the mechanism of that HIF-1α regulates miR-130a transcriptionally by targeting its promoter region; that miR-130a directly targets FRZB to reduce its expression, reduces interaction with ASPN protein and therefore increases the level of ASPN, further activates AKT signaling pathway to promote CCL2 secretion and at last recruits TAMs. Our work should reveal the recruitment and regulation of TAMs by HIF-1α/miR-130a/FRZB-ASPN/CCL2 pathway in hypoxic microenvironment of synovial sarcoma, and the significance of those key factors in the diagnosis and prognostic judgment of synovial sarcoma. It will provide theoretical and experimental basis for targeted therapy of synovial sarcoma.
肿瘤是一种系统性疾病,可导致体内多器官功能异常,特别肝脏。肝外转移倾向的肿瘤(如骨与软组织肿瘤:骨肉瘤、黑色素瘤等)无需转移至肝脏即可通过分泌细胞外囊泡和颗粒(EVP),包括各类亚型Exo-S、Exo-L和Exomere影响肝脏功能。通过抑制控制EVP分泌的关键因子Rab27a可减少脂肪肝形成。EVP在肝内主要由库普细胞(KC)摄取,其内包裹着活性物质棕榈酸(PA)可激活KC表面Tlr4并诱导KC分泌肿瘤坏死因子alpha(TNF-a),形成促炎微环境;TNF-a可抑制肝细胞(HC)脂肪酸代谢和氧化磷酸化、促进脂肪肝形成,同时抑制肝细胞内参与药物代谢的关键酶细胞色素P450(Cyp450),进而增强肿瘤化疗副作用之骨髓抑制和心脏毒性作用,引起化疗耐药。该研究揭示肿瘤通过Tb-EVP(PA)-KC-TNFa-HC-Cyp450/NAFLD引起化疗耐药的新机制,为抑制脂肪肝形成、增强化疗效果提供理论基础。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
Microparticles from Hyperphosphatemia-Stimulated Endothelial Cells Promote Vascular Calcification Through Astrocyte-Elevated Gene-1
来自高磷血症刺激的内皮细胞的微粒通过星形胶质细胞升高的基因 1 促进血管钙化
DOI:10.1007/s00223-022-00960-6
发表时间:2022-02-23
期刊:CALCIFIED TISSUE INTERNATIONAL
影响因子:4.2
作者:Xiang, Yazhou;Duan, Yingjie;He, Zhangxiu
通讯作者:He, Zhangxiu
RNA-seq analysis of extracellular vesicles from hyperphosphatemia-stimulated endothelial cells provides insight into the mechanism underlying vascular calcification.
对高磷血症刺激的内皮细胞的细胞外囊泡进行 RNA 测序分析,有助于深入了解血管钙化的机制
DOI:10.1186/s12882-022-02823-6
发表时间:2022-05-21
期刊:BMC NEPHROLOGY
影响因子:2.3
作者:Peng, Zhong;Duan, Yingjie;Zhong, Shuzhu;Chen, Juan;Li, Jianlong;He, Zhangxiu
通讯作者:He, Zhangxiu
肺IM通过外泌体诱发癌症相关血栓栓塞的机制研究
- 批准号:--
- 项目类别:省市级项目
- 资助金额:30.0万元
- 批准年份:2024
- 负责人:李建龙
- 依托单位:
国内基金
海外基金
